The company said it completed the acquisition of Edwards Lifesciences' Critical Care product group on September 3, 2024 for total consideration of $3.911 billion, and that it renamed the business BD Advanced Patient Monitoring and reports it as a separate organizational unit within the Medical segment.

1. 01

   The company said it completed the acquisition of Edwards Lifesciences' Critical Care product group on September 3, 2024 for total consideration of $3.911 billion, and that it renamed the business BD Advanced Patient Monitoring and reports it as a separate organizational unit within the Medical segment.

2. 02

   The company said worldwide revenues for fiscal 2024 were $20.178 billion, up 4.2% from the prior-year period. It said the increase reflected the effects of foreign currency, the sale of the Surgical Instrumentation platform, and the acquisition of Advanced Patient Monitoring.

3. 03

   The company said it recorded a charge of $28 million to Cost of products sold for estimated future costs after receiving the Dispensing Warning Letter on November 22, 2024. As a result, Operating Income was adjusted from $2.425 billion to $2.397 billion as reported in the Earnings Release, and diluted earnings per share from continuing operations was adjusted from $5.93 to $5.86.

4. 04

   The company said cash flow from continuing operating activities was $3.844 billion in fiscal 2024. As of September 30, 2024, cash and equivalents and short-term investments, including restricted cash, totaled $2.301 billion, and it paid cash dividends to common shareholders of $1.100 billion.

Key figures

Fiscal year ended September 30, 2024

Revenue

$20.2B

Operating income

$2.4B

Net income

$1.7B

EPS

$5.86

Operating cash flow

$3.8B

Analysis scope · Management's discussion (MD&A)We analyzed excerpts of the Management's Discussion and Analysis (MD&A) section (with omissions). Other sections of the report, such as the notes to the financial statements and risk factors, were not reviewed.

AI summarized the filing and translated the summary into English; it may differ from the original. For reference only, not investment advice. AI translated the published Korean report into English. Figures are copied as filed, not recalculated.

Original filing

The filing as submitted to SEC EDGAR. You can check the figures and statements of this summary against it.